Lady Davis Institute for Medical Research, McGill University, Montréal, Quebec, Canada.
UMR INSERM 1260, CRBS, Strasbourg University, Strasbourg, France.
J Thromb Haemost. 2022 Jan;20(1):17-31. doi: 10.1111/jth.15566. Epub 2021 Nov 9.
The COVID-19 pandemic extended all around the world causing millions of deaths. In addition to acute respiratory distress syndrome, many patients with severe COVID-19 develop thromboembolic complications associated to multiorgan failure and death. Here, we review evidence for the contribution of neutrophils, platelets, and extracellular vesicles (EVs) to the thromboinflammatory process in COVID-19. We discuss how the immune system, influenced by pro-inflammatory molecules, EVs, and neutrophil extracellular traps (NETs), can be caught out in patients with severe outcomes. We highlight how the deficient regulation of the innate immune system favors platelet activation and induces a vicious cycle amplifying an immunothrombogenic environment associated with platelet/NET interactions. In light of these considerations, we discuss potential therapeutic strategies underlining the modulation of purinergic signaling as an interesting target.
新冠疫情在全球范围内蔓延,导致数百万人死亡。除急性呼吸窘迫综合征外,许多重症 COVID-19 患者还会发生与多器官衰竭和死亡相关的血栓栓塞并发症。在这里,我们回顾了中性粒细胞、血小板和细胞外囊泡(EVs)在 COVID-19 血栓炎症过程中的作用的证据。我们讨论了受促炎分子、EVs 和中性粒细胞胞外陷阱(NETs)影响的免疫系统如何在重症患者中出现问题。我们强调了先天免疫系统调节不足如何促进血小板活化,并诱导一个恶性循环,放大与血小板/NET 相互作用相关的免疫血栓形成环境。有鉴于此,我们讨论了潜在的治疗策略,强调嘌呤能信号的调节作为一个有趣的靶点。